2022
DOI: 10.4110/in.2022.22.e26
|View full text |Cite
|
Sign up to set email alerts
|

Amelioration of DSS-Induced Acute Colitis in Mice by Recombinant Monomeric Human Interleukin-22

Abstract: IL-22, a pleiotropic cytokine, is known to have a profound effect on the regeneration of damaged intestinal barriers. The tissue-protective properties of IL-22 are expected to be potentially exploited in the attenuation and treatment of colitis. However, because of the disease-promoting role of IL-22 in chronic inflammation, a comprehensive evaluation is required to translate IL-22 into the clinical domain. Here, we present the effective production of soluble human IL-22 in bacteria to prove whether recombinan… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 61 publications
0
3
0
Order By: Relevance
“…38 In contrast to IL-10, the specifically expressed IL-22 in the intestine stimulated the regeneration of epithelial cells and increased the expression of antibacterial proteins, mucins, and tight junction proteins to protect its epithelial barrier. 39 Recently, monomeric IL-22 treatment was reported to inhibit the production of pro-inflammatory cytokines and alleviate DSS-induced acute colitis in mice, 40 and increased serum content and enhanced colonic expression of IL-22 were widely found to be associated with improved colitis phenotypes. 3 Our results revealed that UroA treatment significantly increased serum IL-22 levels, as expected, and decreased the content of IL-10 in serum (Figures 3C and 6F), suggesting that the anticolitis activity of UroA was primarily related to IL-22 in this study.…”
Section: Discussionmentioning
confidence: 99%
“…38 In contrast to IL-10, the specifically expressed IL-22 in the intestine stimulated the regeneration of epithelial cells and increased the expression of antibacterial proteins, mucins, and tight junction proteins to protect its epithelial barrier. 39 Recently, monomeric IL-22 treatment was reported to inhibit the production of pro-inflammatory cytokines and alleviate DSS-induced acute colitis in mice, 40 and increased serum content and enhanced colonic expression of IL-22 were widely found to be associated with improved colitis phenotypes. 3 Our results revealed that UroA treatment significantly increased serum IL-22 levels, as expected, and decreased the content of IL-10 in serum (Figures 3C and 6F), suggesting that the anticolitis activity of UroA was primarily related to IL-22 in this study.…”
Section: Discussionmentioning
confidence: 99%
“…4c). Treatment with recombinant IL-22 ameliorated DSSinduced colitis in WT mice 46 but not in ERdj5-KO mice (Supplementary Fig. 3d).…”
Section: Erdj5 Helps Maintain Gut Barrier Function By Enhancing Tight...mentioning
confidence: 94%
“…The proteins were purified using Ni-NTA agarose affinity chromatography, following the standard protocol. [21] Size-exclusion chromatography using HiLoad® 16/600 Superdex® 75 column (Cytiva, USA) was performed to increase the purity of the proteins. The production and purification of the proteins were examined by SDS-PAGE and the concentration of the purified proteins was determined by Bradford assay.…”
Section: Protein Expression and Purificationmentioning
confidence: 99%